[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Franciscus Gasthuis & Vlietland (Hospital)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630816","phase-2-photo-acoustic-and-ultrasonographic-mammoscope-100630816",false,"NCT07492589","Photo-Acoustic and Ultrasonographic Mammoscope","Photo-Acoustic and Ultrasound MammoScope to Detect Breast Lesions: The PAUS Study","PAUS","Inclusion Criteria:\n\n1. Women\n2. Age \\> 18 years\n3. Referred to the outpatient breast clinic of the Franciscus Vlietland Hospital due to a possible breast lesion\n4. Patients who are fully competent to give written informed consent\n5. Sufficient knowledge of the Dutch language to complete a questionnaire\n\nExclusion Criteria:\n\n1. Currently undergoing chemotherapy\n2. Discharge from the nipple(s)\n3. Breast ulcers or -wounds\n4. Currently suffering from mastitis\n5. Carrier of a resistant bacterium (e.g. Methicillin-resistant Staphylococcus aureus (MRSA) or Multidrug resistant organisms (MDRO; in Dutch: BRMO)\n6. Irremovable piercings on\u002Fin the breast\n7. Pregnancy\n8. Patients whose breasts do not fit in the cup sizes (small breasts can be measured without a cup)\n9. Currently using medication that increases photo-toxicity of the skin or skin care products that increase photosensitivity (e.g. certain antibiotics: tetracyclines or quinolones, certain antidiuretics\n10. A history of photosensitive disease (e.g. porphyria, lupus erythematosus)\n11. Currently undergoing therapy for a photosensitive disease and experiencing photosensitive disease\n12. Currently undergoing phototherapy\n13. Patients with a known allergy for PVC\n14. Patients that are not physically capable of climbing on the examination bed\n15. Patients that are not physically capable of laying on the examination bed during the measurements","FEMALE","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of this study is to evaluate the negative predictive value of the Photo Acoustic Imager 3+ (PAM3+) in the detection of female breast lesions (malignant and benign)in an outpatient setting.",[27,28],"Benign Breast Lesions","Malignant Breast Tumours",[30,15,31],"Photo-acoustic imaging","Fotoakoestiek","RECRUITING","2026-03-19",{"date":35,"type":36},"2026-03-25","ACTUAL",{"date":38,"type":36},"2026-02-01",{"date":40,"type":21},"2028-04-01",{"name":42,"class":43},"Franciscus Gasthuis & Vlietland (Hospital)","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100630155","phase-3-cryoablation-versus-lumpectomy-in-early-stage-breast-cancer-100630155","NCT07483996","Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer","Cryoablation as Alternative for Lumpectomy in Early-Stage Breast Cancer: The CRYSTAL Trial","CRYSTAL","Inclusion Criteria:\n\n1. Women\n2. Age \\> 60 years\n3. Postmenopausal (no menstrual period for at least 12 months or in case of an intra-uterine device (IUD) hormone levels that indicate the menopause: follicle stimulating hormone (FSH) \\> 20 IE\u002Fl and estradiol \\\u003C 100 pmol\u002Fl)\n4. Histopathological confirmed primary invasive ER+\u002FHER2- type breast cancer\n5. Bloom Richardson grade 1 or 2 (low or intermediate malignancy grade)\n6. Unilateral and unifocal breast cancer\n7. A clinical T1N0M0 tumor (≤ 2cm and N0 on US and\u002For MRI), without distant metastases. The largest diameter measured will be used to determine eligibility.\n8. Tumor should be visible and well delineated (all borders of the tumor should be visible) on ultrasound at diagnosis and during the procedure.\n9. Sufficient knowledge of the Dutch language to complete the questionnaires\n10. To be able to give written informed consent\n\nExclusion Criteria:\n\n1. History of invasive breast cancer\n2. Breast augmentation\n3. BRCA-1 or 2 gene mutation carrier\n4. Lobular carcinoma\n5. Triple negative breast cancer\n6. Multifocality\n7. HER2-neu overexpressing tumors\n8. Lymph vascular invasion (LVI) on core needle biopsy or histopathological confirmed after lumpectomy\n9. Indication for neoadjuvant systemic therapy\n10. Intraductal component \\> 25% of the diameter of the invasive tumor on MRI, complete area of the primary tumor should not exceed 2cm.\n11. Allergic to local anesthetics\n12. Electrical devices and\u002For implants that are not compatible with MRI\n13. Current severe breast infection\n14. Uncorrectable coagulopathy\n15. Hemodynamic instability\n16. Respiratory instability\n17. Refraining from adjuvant radiotherapy\n18. Indication for oncoplastic surgery (surgical volume replacement techniques e.g. LICAP)","60 Years",{"count":55,"type":21},938,[57],"PHASE3","The goal of this randomised controlled trial is to compare ipsilateral breast cancer recurrence rates in patients with early-stage breast cancer between patients treated with breast conserving surgery and patient treated with percutaneous cryo-ablation.",[60],"Early-Stage Breast Cancer",[62,60,63,64],"Breast Cancer","Borstkanker","Vroegstadium Borstkanker","NOT_YET_RECRUITING","2026-03-16",{"date":33,"type":36},{"date":69,"type":21},"2026-04-01",{"date":71,"type":21},"2038-12-31",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100533795","fractional-exhaled-nitric-oxide-feno--test-as-add-on-test-in-the-diagnostic-work-up-of-asthma-100533795","NCT06230458","Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma","Care Evaluation Study of the Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma","INFERNO","Inclusion Criteria:\n\n* Patients ≥ 18 years old visiting the outpatient clinic pulmonology with the suspicion of asthma will be asked to participate in this study. For reasons of external validity and generalizability of the study results, it was decided not to exclude subgroups such as smokers or obese patients.\n\nExclusion Criteria:\n\n* Patients with already diagnosed asthma are not allowed to participate.\n* The inclusion of patients with respiratory infections \\\u003C3 weeks ago will be postponed to \\>3 weeks.","ALL",{"count":83,"type":21},171,[85],"NA","The Global Initiative of Asthma Guideline (GINA) recommends a flowchart to diagnose asthma with first-step spirometry with reversibility and a bronchial challenge test (BPT) with histamine or methacholine as a second step.\n\nThis multi-center prospective care evaluation study compares the 'standard asthma diagnostic work-up' (spirometry with reversibility and BPT) to the 'new asthma diagnostics work-up' (FeNO-test as an intermediate step between the spirometry with reversibility and the BPT), intending to determine the impact of the FeNO-based strategy, in terms of the number of avoided BPTs, cost-effectiveness and reduced burden to the patient and health care.\n\nThe cost reduction of incorporating the FeNO-test in the new diagnostic algorithm will be established by the number of theoretically avoided BPT. The decrease in burden will be studied by calculating differences in the Visual Analogue Scale (VAS) -score and Asthma Quality of Life Questionnaire (AQLQ) -score after the BPT and FeNO-test with an independent T-test. The accuracy of the FeNO-test will be calculated by comparing the FeNO-test outcomes to the (gold standard) BPTs outcomes in terms of sensitivity and specificity.",[88,89],"Diagnosis","Asthma",[89,91,92,93,94,95],"Diagnostics","FeNO","Bronchial provocation test","Burdesome","cost-effectiveness","2024-01-20",{"date":98,"type":36},"2024-01-30",{"date":100,"type":36},"2023-10-01",{"date":102,"type":21},"2026-10-01",{"name":42,"class":43},""]